CARDIOVASCULAR BIOTHERAPEUTICS, INC. SUBSCRIPTION AGREEMENTSubscription Agreement • November 16th, 2007 • CardioVascular BioTherapeutics, Inc. • Pharmaceutical preparations
AMENDMENT II to FIRMINVEST AG COMMITMENT LETTERCommitment Letter • November 16th, 2007 • CardioVascular BioTherapeutics, Inc. • Pharmaceutical preparations
This Second Amendment (“Amendment II”), effective as of October 12, 2007 (the “Effective Date”), is attached to and made part of the commitment letter as amended (the “Commitment Letter”) between FirmInvest AG (“FirmInvest”) and CardioVascular BioTherapeutics, Inc., a Nevada corporation (“Cardio”) regarding a foreign private placement being conducted under Regulation S of the Securities Act of 1993 to sell 15,000,000 shares of common stock of CardioVascular BioTherapeutics, Inc. at US$1.00 per shares (the “Reg S Offering”).
CONFIDENTIAL Date: 08/16/07Placement Agent Agreement • November 16th, 2007 • CardioVascular BioTherapeutics, Inc. • Pharmaceutical preparations
GHL Financial Services Ltd., Inc. (“GHL”) is please to be engaged by CardioVascular BioTherapeutics, Inc. (the “Company”) to act as lead placement agent in the proposed offering, issuance and sale of the Company’s securities (the “Securities”) by the Company (the “Transaction”). The term of this letter agreement (the “Agreement”) shall commence on the date hereof and continue until it is terminated by either party given 30 days notice in writing.
